Evidence map›Paper›PMID 36787938›Full record

ArticleJournal for immunotherapy of cancer2023

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.

Dawei Rong, Yuliang Wang, Li Liu, Hengsong Cao, Tian Huang, Hanyuan Liu, Xiaopei Hao, Guangshun Sun, Guoqiang Sun, Zhiying Zheng and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. New insights into T-cell exhaustion in liver cancer: from mechanism to therapy.Journal of cancer research and clinical oncology · 2023
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Dawei Rong *Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Yuliang Wang *School of Basic Medicine, Nanjing Medical University, Nanjing, China.
Li Liu *Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Hengsong Cao *Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Tian HuangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Hanyuan LiuHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Xiaopei HaoHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Guangshun SunHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Guoqiang SunHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Zhiying ZhengHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Junwei KangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Yongxiang XiaHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China wangxh@njmu.edu.cn 1243773473twww@sina.com dr_czy@126.com yx_xia@njmu.edu.cn.ORCID 0000-0001-6589-797X
Ziyi ChenHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China wangxh@njmu.edu.cn 1243773473twww@sina.com dr_czy@126.com yx_xia@njmu.edu.cn.
Weiwei TangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China wangxh@njmu.edu.cn 1243773473twww@sina.com dr_czy@126.com yx_xia@njmu.edu.cn.ORCID 0000-0002-8516-819X
Xuehao WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China wangxh@njmu.edu.cn 1243773473twww@sina.com dr_czy@126.com yx_xia@njmu.edu.cn.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNNanjing Medical University · CNTianjin University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGLI-similar 1 (GLIS1) is one of of Krüppel-like zinc finger proteins, which are either stimulators or inhibitors of genetic transcription. Nevertheless, its effects on T cell were elusive.

methodsIn this study, we intend to explore the effects of GLIS1 on modulating the anticancer potency of CD8

resultsGLIS1 was upregulated in exhausted CD8

conclusionOur study revealed that GLIS1 promoted CD8

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsCD8-Positive T-LymphocytesDNA-Binding ProteinsHumansLeukocytes, MononuclearMiceMice, Inbred C57BLSTAT3 Transcription FactorTranscription FactorsTumor MicroenvironmentDNA-Binding ProteinsGLIS1 protein, humanGlis1 protein, mouseSTAT3 protein, humanSTAT3 Transcription FactorTranscription Factorsbiomarkers, tumordrug therapy, combinationimmunity, cellular

Identifiers

PMID36787938
PMCPMC9930610
OpenAlexW4320730927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.